Opinion|Videos|July 16, 2024
Optimizing Treatment: Expert Insights on Streamlining and Deprescribing for Older Adults with T2D
Key opinion leaders explore methods for optimizing treatment in older adults with type 2 diabetes, focusing on streamlining regimens and the process of deprescribing, with particular emphasis on defining and implementing the deprescribing approach.
Advertisement
Episodes in this series
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
3
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
4
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
5